Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(1), P. 56 - 56

Published: Jan. 3, 2025

Psoriasis, a chronic inflammatory dermatosis, represents significant clinical challenge due to its complex pathogenesis and the limitations of existing therapeutic strategies. Current psoriasis diagnoses are primarily clinician-dependent, with instrumental diagnostics serving as adjuncts. Ongoing research is progressively deciphering molecular underpinnings; future may involve genetic immunological profiling pinpoint biomarkers, enabling more accurate timely interventions. The administration medications, whether oral, injectable, or topical, associated range side effects compliance issues. Topical despite their advantages in patient reduced systemic effects, hindered by altered skin barrier psoriasis, which impedes effective drug penetration retention. In recent years, development novel transdermal delivery systems promising frontier management. Nanotechnology-, microneedle- dressing-based have demonstrated potential for improved penetration, enhanced bioavailability, extended retention time. Here, we will focus on latest insights into etiology, diagnostic methodologies, approaches particular emphasis evolution challenges systems.

Language: Английский

---

Outline of Therapeutic Potential of Different Plants Reported Against Psoriasis via In Vitro, Pre‐Clinical or Clinical Studies

Phytotherapy Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

ABSTRACT Psoriasis is a noncontagious, autoimmune chronic inflammatory disease with an unknown root cause. It classified as multifactorial and skin disorder that also affects the immune system genetic. Environmental factors such stress, infections, injuries all play important role in disease's development. Although there no cure for this disease, topical, oral, systemic whole‐body treatments are available to relieve symptoms. Several plants phytochemicals which have been found effective management of psoriasis experimentally (preclinical clinical). These plants/phytochemicals applications treatments. Traditionally, some utilized primary treatment, including their extracts and/or phytochemicals, individuals moderate severe (due fewer side effects), while phototherapy generally reserved more advanced cases. This report describes various be against vitro, preclinical, clinical studies. review summarizes key findings from experimental studies on pathological aspects may useful, effective, informative future research.

Language: Английский

---

Clinical application of biological agents in rheumatoid arthritis

Transplant Immunology, Journal Year: 2025, Volume and Issue: unknown, P. 102187 - 102187

Published: Jan. 1, 2025

Language: Английский

---

Pharmacotherapy of arterial hypertension in patients with psoriasis

Journal of Hypertension, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 18, 2025

Psoriasis is a chronic systemic autoimmune disease associated with an elevated risk of developing cardiovascular disease. In patients psoriasis, arterial hypertension treatment requires careful selection antihypertensive drugs, as some drugs may worsen the skin manifestations psoriasis. this review, we summarize available evidence regarding risks and benefits each group drugs. We also suggest scheme for optimizing in emphasis on achieving effective control blood pressure disease, while minimizing worsening cutaneous manifestations. Angiotensin receptor blockers appear to be most appropriate hypertensive potential addition calcium channel if not adequately controlled. Alternatives are angiotensin-converting enzyme inhibitors and/or mineralocorticoid antagonists. Diuretics beta greater psoriatic lesions.

Language: Английский

---

Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Tyrosine kinase 2 (TYK2), a critical scaffolding required for type I interferon, IL-12 and IL-23 cytokine signaling, represents compelling therapeutic target various autoimmune diseases. However, existing TYK2 inhibitors only modulate its activity. Here, we report the development of first series CRBN-recruiting PROTACs based on an allosteric inhibitor. Optimization potency metabolic stability identified 15t as exceptionally potent selective degrader with DC50 value 0.42 nM Dmax 95%, which potently selectively blocked TYK2-dependent signaling. Importantly, was active in vivo significantly suppressed TYK2-mediated pathology murine psoriasis model without apparent toxicity. Collectively, our study provides potentially valuable chemical knockdown probe subtype-selective degradation further understanding biology, demonstrating potential immuno-inflammatory diseases such psoriasis.

Language: Английский

---

Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives

Experimental Dermatology, Journal Year: 2025, Volume and Issue: 34(4)

Published: April 1, 2025

ABSTRACT JAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations associated with an increased risk of major adverse events. Ruxolitinib 1.5% cream is a selective topical JAK1 and JAK2 inhibitor, which has recently been approved by EMA MHRA for treating non‐segmental vitiligo, while being FDA‐approved both vitiligo atopic dermatitis. Recent literature reported the off‐label use several conditions, but data mostly limited single case reports series few prospective studies, mixed results. We conducted systematic review investigate potential efficacy in diseases setting. The following keywords were searching MEDLINE (Pubmed) Scopus databases from inception September 2024: “ruxolitinib dermatology” “topical ruxolitinib dermatology”. Reviews, articles not focusing on main topic, books book chapters, no English text excluded. A total 170 studies screened, 112 fell within exclusion criteria 58 assessed eligibility. Of these, 28 published between 2012 2024, selected. resulted lichenoid granulomatous dermatoses, as well alopecia areata. While former proved be effective safe, results areata controversial. Topical might promising therapeutic option dermatoses. Noteworthily, despite exciting oral formulation, consistent described Our encouraging many conditions that should investigated further studies.

Language: Английский

---

Decoy oligodeoxynucleotides targeting STATs in non-cancer gene therapy

Gene, Journal Year: 2025, Volume and Issue: unknown, P. 149482 - 149482

Published: April 1, 2025

Language: Английский

---

Association between Life’s Essential 8 and psoriasis in US adults: a cross-sectional study

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Oct. 10, 2024

Psoriasis is closely associated with cardiovascular disease (CVD). However, the current evidence on correlation between Life's Essential 8 and insufficient. Our aim was to investigate relationship (LE8), a measure of health (CVH), psoriasis.

Language: Английский

---

Study on the Mechanism of Compound Zeqi Granule in Treating Psoriasis vulgaris Based on Network Pharmacology and Experimental Verification

Natural Product Communications, Journal Year: 2024, Volume and Issue: 19(11)

Published: Nov. 1, 2024

Background This study used a holistic network pharmacological approach to clarify the mechanism of Compound Zeqi Granule (CZG) in treating psoriasis vulgaris (PV). Methods The potential bioactive compounds and corresponding targets CZG were collected searched via TCMSP database. Disease PV obtained from GeneCards standardized by UniProt GO KEGG enrichment analyses performed using Metascape Then, molecular docking verification was conducted CB-Dock Animal experiments validate effects on PV. Results identified 99 compounds, 579 drug targets, 822 PV-related 108 target proteins. biological processes primarily related regulation defense response, inflammatory responses, cellular response lipid. for significantly associated with 20 pathways including JAK-STAT signaling pathway. confirmed that exerted its therapeutic promoting expression IL-10 JUN, inhibiting activation STAT1 STAT3. Conclusion present provides evidence supporting efficacy treatment through multi-compound, multi-target multi-pathway lays theoretical foundation further experimental research this field.

Language: Английский

---

A Case Series Report on the Effect of Tofacitinib on Joint Inflammation and Gut Microbiota Composition in Psoriatic Arthritis Patients Naive to Biologic Agents

Microorganisms, Journal Year: 2024, Volume and Issue: 12(12), P. 2387 - 2387

Published: Nov. 21, 2024

Introduction: Psoriatic arthritis (PsA) is a complex condition within the Spondyloarthritis (SpA) group. Recent studies have focused on important role of intestinal microbiota in maintaining immunological homeostasis, highlighting how dysbiosis may act as trigger for autoimmune diseases. Tofacitinib Janus kinase inhibitor (JAK-i) with proven efficacy treatment both rheumatoid and PsA. However, there lack data its ability to reduce joint remission through ultrasonography (US) effects it might composition gut microbiota. Methods: Here, we present case series seven bio-naïve PsA patients who received tofacitinib were followed up 12 months. The clinical response was assessed using validated scores (DAPSA, ASDAS, BASDAI), laboratory tests, US assessment target enthesis. Finally, evaluated changes next-generation sequencing analysis fecal samples. Results: study showed significant improvement all used; this also confirmed by reduction synovitis scores. suggested that effectiveness ameliorating activity associated relevant modification some bacterial lineages. No cases severe adverse reported. Conclusions: Treatment proved be effective, safe capable varying selecting strains considered beneficial immune modulation.

Language: Английский

---